On February 1, 2022 Abcam plc ("Abcam", "Company", "Group") (AIM: ABC; Nasdaq: ABCM), a global leader in the supply of life science research tools, reported that the following trading update ahead of reporting its financial results in March (Press release, Abcam, FEB 1, 2022, View Source [SID1234607554]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Group expects to report total revenues for the 12 months ended 31 December 2021 of approximately £315 million, representing growth of over 22% on a constant exchange rate (CER) basis and 17% on a reported basis (12 months to 31 December 2020: £269.3 million). This figure includes a contribution of approximately £2.5 million of incremental revenue1 from BioVision following the acquisition’s completion on 27 October 2021.

Revenue growth continues to be driven by demand for the Company’s proprietary products, with in-house catalogue sales up approximately 37% CER on an organic basis (43% including BioVision), together with a continued recovery in global lab activity. Whilst risks related to the pandemic remain – as evidenced by the emergence of the Omicron variant in late 2021 – data indicates that, while not yet returning to pre-covid levels, overall lab activity continued to increase through 2021.

The Group has continued to build capabilities, invest in innovation and implement its multi-year growth strategy throughout the period. Overall, we anticipate adjusted operating profits will be reported in line with the board’s expectations for the period and we remain on track to achieve our financial goals for the five year plan ending in 2024.

Following the change in the Company’s financial year end to 31 December, full results for the 18 month period ended 31 December 2021 will be released on 14 March 2022. In order to aid comparison, pro forma information for the 12 month periods ended 31 December 2021 and 31 December 2020 will also be provided.

Alan Hirzel, CEO of Abcam commented:

"2021 was a year of significant innovation and growth in proteomic tools and discovery. I thank our customers for trusting Abcam as their preferred partner and our global colleagues for their unwavering dedication to customer needs and aspirations. Together, we are building a durable enterprise that is making a difference in the pace and social impact of discovery. I am confident in our progress toward our 2024 business goals and I look forward to providing the full update in March."

1 Incremental revenue excludes sales of BioVision products through Abcam channels

This announcement contains inside information which is disclosed in accordance with the Market Abuse Regulation.

On February 1, 2022 Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences reagents and tools and Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, reported a licensing agreement under which Abcam will use a proprietary Twist VHH phage library for antibody discovery, development and commercialization for diagnostic and research applications (Press release, Abcam, FEB 1, 2022, View Source [SID1234607553]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Phage display complements other antibody discovery methods, and offers several benefits for tackling challenging targets. The synthetic nature and the diversity of each Twist library (up to 10 billion variants) enable the rapid identification of antibodies against challenging targets that would otherwise fail due to toxicity or lack of immunogenicity. The recombinant format enables easier genetic engineering and maximizes in vitro manufacturing ensuring batch-to-batch reproducibility and scalability from bench to bedside.

"Twist’s phage library complements our leading recombinant antibody discovery capabilities, adding further scale and diversity and increasing the likelihood of identifying antibodies with the desired properties against emerging or established targets. The partnership supports Abcam and Twist’s commitment to deliver antibodies that have the potential to accelerate the development of innovative research tools, diagnostics and therapeutics."
Alejandra Solache, Ph.D
SVP R&D at Abcam

Under the terms of the agreement, Twist Bioscience grants Abcam the right to engage in research and development activities using Twist single domain (VHH) synthetic antibody library. Abcam has the option to nominate, license and commercialize antibody sequences for diagnostic and research use, in return for license fees and commercial milestone payments. Twist retains the rights to the same sequences for therapeutic application.

"This partnership is an important milestone in Twist’s journey as it allows us to access the research and diagnostic market through Abcam’s commitment to advance discovery, development and commercialization of the resulting antibodies. In addition, this agreement lays the foundations for a long term collaboration with Abcam to drive new commercial opportunities. Importantly, because Twist retains the rights to develop the sequences for therapeutic uses, this partnership has the potential to benefit our internal pipeline as well."
Emily M. Leproust, Ph.D
CEO and co-founder of Twist

(1) VHH Antibody Libraries

Antibodies contain two variable domains, the heavy and the light chains. A VHH antibody, also known as a nanobody or single domain antibody, is the antigen binding domain of the heavy chain, with three complementary determining regions (CDRs), or areas where antigens bind to the antibody. Twist’s VHH library uses novel methods that combine synthetic and natural approaches to maximize diversity in the 10 billion antibody library, creating high quality VHH libraries for use against any protein target. The small size of the VHH antibodies allow them to access targets that traditional antibodies cannot, with tight binding affinity.

On February 1, 2022 Tollys Presented the Corporate Presentation (Presentation, Tollys, FEB 1, 2022, View Source [SID1234607551])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On February 1, 2022 Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, reported that it has entered into a two-year research collaboration with Prof. Michael Uhlin of the Department of Clinical Science, Intervention and Technology at Karolinska Institutet in Stockholm, Sweden, to develop and characterize novel ONCOS oncolytic viruses (Press release, Targovax, FEB 1, 2022, View Source [SID1234607550]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Uhlin is a professor of clinical immunology at Karolinska Institutet specializing in onco-immunology, transplantation and lymphocyte biology. Under the collaboration agreement with Targovax, Prof. Uhlin will establish and coordinate a research team dedicated to pre-clinical in vitro and in vivo evaluation of novel ONCOS oncolytic adenoviruses, including circular RNA delivery vectors. The research collaboration has an initial term of two years, which may be extended if successful.

Dr. Victor Levitsky, Chief Scientific Officer of Targovax, said: "Prof. Uhlin is a highly accomplished scientist with deep experience in translational and clinical immunology. His expertise and research capabilities will play a critical role as we build our portfolio of next generation ONCOS constructs over the coming years. To achieve our ambitious goals of expanding into novel immunotherapy mechanisms, such as circular RNA delivery, access to high-caliber scientists with the relevant skill-set and state-of-the-art infrastructure will be essential. This is precisely what we get through this collaboration with the Karolinska Institute."

Prof. Michael Uhlin, Group Leader at the Department of Clinical Science, Intervention and Technology at Karolinska Institutet, added: "The team at Targovax has generated a compelling set of clinical data for their lead candidate ONCOS-102, which they are now applying to enhance their platform with next generation armed viral immunotherapies. I find it highly scientifically interesting to support Targovax in understanding the biology and immunological activity of this innovative class of oncolytic delivery vectors. It will be exciting to participate in the characterization and optimization of novel ONCOS candidates as potential future treatment options for patients with challenging solid tumors".

On January 28, 2022 Nippon Kayaku reported that Summary of Consolidated Financial Results [Japanese GAAP] For the Third Quarter of the Fiscal Year Ending March 31, 2022 (Press release, Nippon Kayaku, FEB 1, 2022, View Source [SID1234607549])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1. Consolidated Business Results for the First Three Quarters of the Fiscal Year Ending March 31, 2022 (April 1, 2021–December 31, 2021)
(2) Consolidated Financial Position

2. Status of Dividends3. Consolidated Business Results Forecasts for the Fiscal Year Ending March 31, 2022 (April 1, 2021–March 31, 2022)

Notes
(1) Significant changes in subsidiaries during the first three quarters (changes in designated subsidiaries that result in changes in scope of consolidation): None
(2) Adoption of special accounting methods for presenting the quarterly consolidated financial statements: None
(3) Changes to accounting policies and estimates and restatements

[1] Changes to accounting policies associated with revision of accounting standards or similar items: Yes
[2] Changes other than
[1]: None
[3] Changes to accounting estimates: None
[4] Restatements: None Note: See

"2. Quarterly Consolidated Financial Statements and Notes to Quarterly Consolidated Financial Statements,
(3) Notes to Quarterly Consolidated Financial Statements (Changes to Accounting Policies)" on page 8 for further details.
(4) Number of shares issued (common stock)
[1] Number of shares issued at end of the fiscal period (including treasury stock) As of December 31, 2021: 177,503,570 shares As of March 31, 2021: 177,503,570 shares
[2] Number of treasury stock at end of the fiscal period As of December 31, 2021: 9,257,789 shares As of March 31, 2021: 6,710,650 shares
[3] Average number of shares during the fiscal period (cumulative) First three quarters of fiscal year ending March 31, 2022: 169,174,386 shares First three quarters of fiscal year ended March 31, 2021: 170,793,503 shares

*Quarterly summary financial statements are not subject to audit by a certified public accountant or audit firm. *Analysis related to appropriate use of the business results forecasts, and other notes (Disclaimer concerning forward-looking statements) The information in this report constitutes forward-looking statements regarding future events and performance.

This information is based on the beliefs and assumptions of management in light of information currently available to it at the time of announcement and subject to a number of uncertainties that may affect future results. Actual business results may differ substantially from the forecasts herein due to various factors. For matters pertaining to business forecasts, please refer to
"(3) Analysis of Forward-looking Statements, Including Consolidated Business Forecasts" on page 3 of the Supplementary Information.